Stephen Parker DPhil, MBA - Non-executive Chairman

Dr Stephen Parker, aged 59, has a career in the healthcare and pharma sector that spans over 30 years, including six years in the City in advisory roles. He has sector corporate finance experience having been an investment banker focusing on pharma and biotechnology with Barings, Warburg and Apax Partners and has previously held roles as a partner at Celtic Pharma and Chief Financial Officer of Oxford GlycoSciences. Stephen is also a Non-executive Director at Silence Therapeutics plc.

Tim Mitchell PhD - Founder and CEO

Dr Tim Mitchell, aged 57, has a wide breadth of management, business and research expertise gained over 30 years in the biotech, large pharmaceutical and research service companies.

He is the inventor of Oblean® (cetilistat) for which Takeda have obtained sales approval in the Japanese market for the treatment of obesity with complications.

Prior to co-founding Sareum he was Director of Structure-Based Discovery at Millennium Pharmaceuticals, Director of Computational Chemistry at Cambridge Discovery Chemistry, and Team Leader at SmithKline Beecham Pharmaceuticals. Tim has a PhD in Computational Chemistry and a BSc in Chemistry.

John Reader PhD - Founder and CSO

Dr John Reader, aged 51, has 25 years' experience within the industry. His previous roles include Associate Director, Chemical Technologies at Millennium Pharmaceuticals Research and Development Ltd, Pharmacopeia Inc., and Cambridge Discovery Chemistry.

John has an excellent track record of delivering successful drug research projects. He has authored or co-authored many publications and patents on small molecule drug discovery. John is a member of the EPSRC Peer Review College and has a PhD in Chemistry and a BSc in Applied Chemistry.

Scientific Advisory Board

Harry Finch PhD

Dr Finch has many years’ experience in the Pharmaceutical industry and is currently Executive Vice President at Pulmagen Therapeutics. He was previously Executive VP of Argenta Discovery, a Director at RiboTargets and spent 24 years at GlaxoSmithKline and its predecessor companies, latterly as Director of Chemistry for UK Research & Development.

Harry has extensive experience in a wide range of therapeutic areas. He was a co-inventor of Salmeterol (Serevent; GSK), a successful long-acting bronchodilator for asthma and has 45 patents and 49 publications to his name.

Bob Jackson PhD

Dr Jackson was formerly Chief Scientific Officer at the cancer drug discovery company, Cyclacel Limited. Prior to that, he held senior research positions at Celltech, Agouron, DuPont and Warner-Lambert. Dr Jackson has led teams that have developed 26 compounds to clinical trials, including the Aurora Kinase inhibitor CYC116, and gained his PhD in biochemistry from the University of London.

  • @Sareumplc Latest tweet

    Roche's discontinuation of its CHK1 inhibitor, RG7741 (aka Genentech's GDC-0575), means this mechanism is now a two… via @Sareumplc
    View more